secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001628280-24-031923
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option
--------------------------------------------------------------------------------

- Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.
- She will lead Phase 2 LOTUS Trial for AVTX-009 in hidradenitis suppurativa.
- Base salary of $500,000, target bonus of 40%, and inducement stock option for 234,000 shares vesting over 4 years.
- Severance includes nine months' salary (12 months post-change-in-control), full option vesting, and COBRA.
- Appointment effective July 15, 2024; employment agreement filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/0001628280-24-031923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/avtx-20240715.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-031923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer